The $1B TB market currently forces payers to buy two tests for one answer. Papyrus Mutacheck Pro consolidates this into a single 'Result-to-Regimen' consumable.
Papyrus Diagnostics Pvt Ltd is a Bengaluru-based startup and an IISc Bangalore spin-off. It is building a unified molecular diagnostics platform spanning TB, NTM, and AMR, with the goal of converting fragmented multi-step algorithms into a single actionable output ("result-to-regimen"). The platform has progressed from the lab to preliminary clinical trials at NIRT, Chennai, and is expected to be ready for formal clinical and regulatory evaluation by Q4 2026.
Grants: global web icon, BIRAC Biotechnology Ignition Grant, Atal Innovation Mission (NITI Aayog), Honeywell CSR, ThoughtWorks CSR. Dilutive funding: C-CAMP, ISICL (FSID - IISc, Bangalore).
Patent pending (India Patent filed). Core IP: NALFA platform for rapid, user-friendly nucleic acid lateral flow readout and multiplex detection.
C-CAMP AMR Diagnostics Idea Challenge 2022, semi-finalist; XPRIZE Rapid COVID Testing Competition (2020); technology was declared as Breakthrough of the Year 2022.
The company was co-founded by an IISc Bangalore faculty member and has been incubated at IISc, Bangalore, IIM-Bangalore, and Venture Centre-Pune, and is part of InDx-CCAMP.
CEO
Co-founder
